B

Bonus Biogroup Ltd
TASE:BONS

Watchlist Manager
Bonus Biogroup Ltd
TASE:BONS
Watchlist
Price: 9.9 ILS 1.02% Market Closed
Market Cap: 121.1m ILS
Have any thoughts about
Bonus Biogroup Ltd?
Write Note

P/E
Price to Earnings

-4.1
Current
-6.4
Median
22.1
Industry
Higher than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-4.1
=
Market Cap
121.1m ILS
/
Net Income
-29.2m ILS
All Countries
Close
Market Cap P/E
IL
Bonus Biogroup Ltd
TASE:BONS
121.1m ILS -4.1
FR
Pharnext SCA
OTC:PNEXF
6T USD -181 287
US
Abbvie Inc
NYSE:ABBV
315.2B USD 62
US
Amgen Inc
NASDAQ:AMGN
141.9B USD 33.5
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD 923.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD -217.7
US
Epizyme Inc
F:EPE
94.1B EUR -471.3
AU
CSL Ltd
ASX:CSL
135.9B AUD 32.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD 16.9
US
Seagen Inc
F:SGT
39.3B EUR -54.6
NL
argenx SE
XBRU:ARGX
35.6B EUR -133.7
Earnings Growth P/E to Growth
IL
B
Bonus Biogroup Ltd
TASE:BONS
Average P/E: 213.7
Negative Multiple: -4.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 287 N/A N/A
US
Abbvie Inc
NYSE:ABBV
62
413%
0.2
US
Amgen Inc
NASDAQ:AMGN
33.5
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
923.6
77%
12
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -217.7
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -471.3 N/A N/A
AU
CSL Ltd
ASX:CSL
32.2
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -133.7 N/A N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
N/A
2-Years Forward
P/E
N/A
3-Years Forward
P/E
N/A

See Also

Discover More